Leave message
Can’t find what you’re looking for?
Fill out this form to inquire about our custom protein services!
Inquire about our Custom Services >>
This protein carries no "tag".
The protein has a calculated MW of 62.6 kDa. The protein migrates as 60 kDa±3 kDa when calibrated against Star Ribbon Pre-stained Protein Marker under reducing (R) condition (SDS-PAGE).
>95% as determined by SDS-PAGE.
>90% as determined by SEC-HPLC.
Supplied as 0.2 μm filtered solution in 12.5 mM Citric acid, pH6.2 with glycerol as protectant.
Contact us for customized product form or formulation.
This product is supplied and shipped with dry ice, please inquire the shipping cost.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
Recombinant Fibronectin fragment, premium grade on SDS-PAGE under reducing (R) and non-reducing (NR) conditions. The gel was stained with Coomassie Blue. The purity of the protein is greater than 95% (With Star Ribbon Pre-stained Protein Marker).
The purity of Recombinant Fibronectin fragment, premium grade (Cat. No. FIN-H5116) was greater than 90% as determined by SEC-HPLC.
Biotinylated Human ITGA4&ITGB1 Heterodimer Protein, His,Avitag&Tag Free (Cat. No. IT1-H82W1) immobilized on SA Chip can bind Recombinant Fibronectin fragment, premium grade (Cat. No. FIN-H5116) with a typical affinity constant of 0.547 μM as determined in a SPR assay (Biacore 8K) (QC tested).
Biotinylated Human ITGA5&ITGB1 Heterodimer Protein, His,Avitag&Tag Free (Cat. No. IT1-H82Wa) immobilized on SA Chip can bind Recombinant Fibronectin fragment, premium grade (Cat. No. FIN-H5116) with a typical affinity constant of 38.2 nM as determined in a SPR assay (Biacore 8K) (QC tested).
Recombinant Fibronectin fragment, premium grade (Cat. No. FIN-H5116) immobilized on CM5 Chip can bind Heparin Sulfate with a typical affinity constant of 0.103 μM as determined in a SPR assay (Biacore 8K) (QC tested).
Recombinant Fibronectin fragment, premium grade (Cat. No. FIN-H5116) could promote mesenchymal stem cell attachment and proliferation in several passages, comparable with Competitor T. The bioactivity of Recombinant Fibronectin fragment, premium grade (Cat. No. FIN-H5116) is similar to GMP Recombinant Human Fibronectin fragment (Cat. No. GMP-FINH18).
Recombinant Fibronectin fragment, premium grade (Cat. No. FIN-H5116) could maintain the stemness of MSC in several passages, with high expression of MSC markers CD73, CD90 and CD105 and negative expression of HLA-DR, CD34 and CD45. The stemness ability of Recombinant Fibronectin fragment, premium grade (Cat. No. FIN-H5116) is comparable with Competitor T and similar to GMP Recombinant Human Fibronectin fragment (Cat. No. GMP-FINH18).
2e5 Jurkat cells were transfected with pLenti-CMV-EGFP-puro-Amp for 48 hours in the presence or absence of Fibronectin fragment, premium grade (Cat. No. FIN-H5116)-coated. The GFP fluorescence was detected with FACS. The Alexa Fluor 488 signal was used to evaluate the expression of GFP+ Jurkat cells (Routinely tested).
CD34+ CD45+ hematopoietic cells were seeded on GMP Recombinant Human Fibronectin fragment (Cat. No. GMP-FINH18) combined with GMP Human DLL4 Protein, Fc Tag (Flagship) (Cat. No. GMP-DL4H27) and GMP Human VCAM-1 Protein, Fc Tag (Cat. No. GMP-VC1H25) coated plates and differentiated for 21 days, then flow cytometry was used to detect the expression of T-cell progenitor markers, CD5 and CD7. GMP Recombinant Human Fibronectin fragment (Cat. No. GMP-FINH18) combined with GMP Human DLL4 Protein, Fc Tag (Flagship) (Cat. No. GMP-DL4H27) and GMP Human VCAM-1 Protein, Fc Tag (Cat. No. GMP-VC1H25) can induce the formation of CD7+ and CD5+ CD7+ T-cell progenitors. The bioactivity of GMP Recombinant Human Fibronectin fragment (Cat. No. GMP-FINH18) is similar to Recombinant Fibronectin fragment, premium grade (Cat. No. FIN-H5116), as well as the competitor T. Negative control: w/o Human Fibronectin.
Emerging VoCs, Omicron, Delta, Beta, Alpha mutants and so on, including RBD, S trimer, S1, NTD, NP, etc. These mutants are of high purity and bioactivity and can be used to evaluate the efficacy of the antibodies and vaccination.
ACROBiosystems developed a series of GMP grade cytokines under the GMP grade quality management system. Those products are all suitable for T/NK cell generation, activation, and proliferation in cell therapy research.
50+ targets designed for CAR detection, including PE/FITC/biotin labeled proteins. The key reagents for CD19 and BCMA were FDA DMF filed which can support your IND, NDA and BLA process.
GMP grade cytokines, reagents for cell activation, gene edition, DNA/RNA removal, etc. Particularly focus on product design, quality control and solution-based support to link each phase of your cell and gene therapy journey.
Full length multi-pass TPs with stabilized structure and high bioactivity for immunization, antibody screening, cell based assay and CAR detection, including hot CD20, Claudin 18.2， CD133, GPRC5D，CCR8, CCR5, etc.
CD3 proteins and a collection of for bispecific antibody development which are of high specificity and bioactivities and suitable for immunization, antibody screening.
A series of immune checkpoints including classic co-inhibitory and co-stimulatory receptors. The comprehensive catalog contains 100+ targets with various species and tags, and the high-quality proteins are in good batch-to-batch consistency.
To meet the needs of ADCs development, ACROBiosystems can provide: A variety of high-quality target proteins; MMPs/Cathepsin/uPA for cleavable linker; Anti-payload antibodies & anti-idiotypic antibodies for immunogenicity and PK analysis; SPR/BLI analytical and ADA development service.
Comprehensive collection of Fc receptor proteins, including their common variants, which can help expedite your antibody development.
The MABSOL biotinylated protein collection includes more than a hundred commonly studied drug targets and biomarker proteins.
Comprehensive cytokines including IL families, growth factors, chemokines, TNFs, etc. These products are HEK293 expressed and nearly in authentic structure, high purity and bioactivity, cell based assay/SPR/BLI verified.
To support preclinical/clinical immunogenicity and PK analysis, ACROBiosystems has developed a series of high-affinity anti-idiotypic antibodies. Our pipeline covers five hot targets including adalimum*b, rituxim*b, cetuxim*b, trastuzum*b, and bevacizum*b.
This web search service is supported by Google Inc.
A-Z
